Inflammopharmacology最新文献

{"title":"Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington's disease.","authors":"Nada Ezeldine-Elmahalawy, Noha F Abdelkader, Hala F Zaki, Amany I Elbrairy, Sameh S Gad","doi":"10.1007/s10787-025-01933-5","DOIUrl":"https://doi.org/10.1007/s10787-025-01933-5","url":null,"abstract":"<p><p>The neuroprotective potential of tyrosine kinase inhibitors (TKIs), potent anticancer drugs, was verified against various neurodegenerative insults, but not Huntington's disease (HD). These promising outcomes were due to their ability to modulate various intracellular signalling pathways. Hence, the current study aimed to evaluate the neuroprotective effects of lapatinib and pazopanib in the 3-nitropropionic (3-NP)-induced HD model in rats. After 14 days of 3-NP administration, rats received saline, lapatinib, or pazopanib for 21 days. Treatment with lapatinib or pazopanib improved the striatal microscopic architecture, neuronal survival, and neuroinflammatory responses, with a pronounced effect observed for pazopanib. At the molecular level, lapatinib and pazopanib reduced the striatal gene expression of NF-κB and TNF-α receptors, curbed the glutamate/calpain-2 axis, and modified the striatal content of inflammatory molecules as well as neurotransmitters. In addition, they activated the neuroprotective trajectory viz., m-Tor/ULK-1/Beclin-1/LC3-II, an effect dependent on tyrosine kinase inhibition. Moreover, treated groups showed normalised tyrosine hydroxylase and glial fibrillary acidic protein in the striatum. In conclusion, this study provides strong evidence that lapatinib or pazopanib significantly improved motor function, alleviated cognitive decline, and attenuated neurodegeneration in HD rats via modulating key signalling pathways implicated in HD pathogenesis. These results underscore the promising therapeutic potential of TKIs in managing HD and warrant further investigation into their clinical application.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation.","authors":"Surya Nath Pandey, M Arockia Babu, Kavita Goyal, Soumya V Menon, Subhashree Ray, Mandeep Kaur, Swati Sharma, Mohit Rana, A Rekha, Haider Ali, Sachin Kumar Singh, Gaurav Gupta","doi":"10.1007/s10787-025-01926-4","DOIUrl":"https://doi.org/10.1007/s10787-025-01926-4","url":null,"abstract":"<p><p>The NOD‑like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a key molecular complex that amplifies inflammatory cascades by maturing interleukin‑1 beta (IL-1β) and interleukin‑18 (IL-18) and inducing pyroptosis. It serves as a major driver and co-driver of numerous diseases associated with chronic inflammation. Dysregulated NLRP3 activation contributes to the progression of disorders such as rheumatoid arthritis, inflammatory bowel disease, neurodegenerative diseases and atherosclerosis. Curcumin, a natural polyphenol derived from Curcuma longa, offers a promising approach to inhibit NLRP3-induced inflammation owing to its multi-targeted actions and excellent safety profile. Preclinical models have demonstrated that curcumin inhibits nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF-κB) signaling, reduces mitochondrial reactive oxygen species (ROS) generation, and suppresses caspase-1 activation and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) assembly, thereby inhibiting inflammasome activation. Curcumin has successfully prevented IL-1β-induced biological effects, tissue damage, and clinical manifestations in models of arthritis, colitis, and Alzheimer's disease (AD). In addition, advanced nanoformulations and structural analogs have enhanced their bioavailability and therapeutic reach. Here, we present a mechanistically focused, curcumin-oriented review synthesizing current knowledge on the NLRP3 inflammasome and its role in chronic inflammatory diseases. We also critically evaluated nanoformulations, curcumin analogs, and combination therapies and integrated evidence from rheumatologic, gastrointestinal, neurodegenerative, metabolic, and cardiovascular models. Furthermore, we explored the molecular mechanisms underlying the therapeutic effects of curcumin and highlighted the challenges of its clinical translation, offering insights for designing precision anti-inflammasome strategies to advance inflammation therapeutics.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint disorders and ozone therapy: some comments.","authors":"Marianno Franzini, Luigi Valdenassi, Salvatore Chirumbolo","doi":"10.1007/s10787-025-01935-3","DOIUrl":"https://doi.org/10.1007/s10787-025-01935-3","url":null,"abstract":"","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of pentoxifylline on serum levels and gene expression of inflammatory markers: a systematic review and meta-analysis of randomized controlled trials.","authors":"Banafsheh Safizadeh, Sahar Yarahmadi, Farzad Sadri, Elham Bahreini, Yaser Mohammadi, Taraneh Rezaei","doi":"10.1007/s10787-025-01936-2","DOIUrl":"https://doi.org/10.1007/s10787-025-01936-2","url":null,"abstract":"<p><strong>Background: </strong>Pentoxifylline (PTX), a methylxanthine derivative, has been recognized as a potential anti-inflammatory treatment across various conditions, yet its effects on inflammatory markers remain inconsistent. This systematic review/meta-analysis evaluated the impact of PTX on serum levels and gene expression of key inflammatory markers in randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Scopus, Embase, Web of Science, and ProQuest up to May 2025. Search results were screened in two stages by two independent reviewers. Data was extracted and the quality of the studies included was assessed using the Cochrane Risk of Bias (RoB) tool. Statistical analysis was performed using STATA -17. The present study was conducted in accordance with the PRISMA guidelines.</p><p><strong>Results: </strong>This study included 81 RCTs involving 7,058 participants. PTX treatment significantly reduced serum levels of CRP (SMD = -0.30, 95% CI: -0.47 to -0.13), IL-6 (SMD = -0.51, 95% CI: -0.81 to -0.22), TNF-α (SMD = -0.72, 95% CI: -0.95 to -0.48), and IL-8 (SMD = -1.14, 95% CI: -1.94 to -0.33) compared to controls. No statistically significant effects were observed for IL-1β, ESR, IL-10, or TNFR. High heterogeneity was noted in most outcomes, partly attributed to variations in age, treatment duration, dosage, geographic region, and health conditions. Subgroup analyses revealed that younger patients, shorter interventions, and lower PTX doses were associated with stronger anti-inflammatory responses.</p><p><strong>Conclusion: </strong>PTX reduces TNF-α, IL-6, IL-8, and CRP, supporting its role in chronic inflammatory diseases. Efficacy varies by age, dose, duration, geography, and disease, requiring personalized treatment. Contradictory biomarker effects and study limitations warrant high-quality trials with standardized protocols.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of low omega-6/omega-3 ratio and high omega-9/omega-6 ratio oil blend on inflammation and oxidative stress after tooth extraction in rats.","authors":"Radamés Bezerra Melo, Gabriella Alves Julião Costa, Paulo Goberlânio de Barros Silva, Reinaldo Barreto Oriá, Cristhyane Costa de Aquino, Paulo Roberto Leitão Vasconcelos","doi":"10.1007/s10787-025-01892-x","DOIUrl":"https://doi.org/10.1007/s10787-025-01892-x","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the effects and mechanisms of antioxidant and anti-inflammatory oils with a high omega-9:omega-6 ratio and a low omega-6:omega-3 ratio on post-extraction healing in rats.</p><p><strong>Materials and methods: </strong>A total of 128 Wistar rats were divided into four groups: Sham, Saline, Isolipidic, and Anti-inflammatory/Antioxidant. The animals received one of the following treatments: (1) 0.9% NaCl solution (Sham Group or Saline Group); (2) an isolipidic mixture containing alpha-linolenic acid (ALA) and a combination of ω-9, ω-6, and ω-3 fatty acids derived from corn oil and soybean oil-rich in omega-6:omega-3 and omega-9:omega-6 ratios (Isolipidic Group); or (3) an anti-inflammatory and antioxidant mixture containing ALA, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), composed of olive oil (61%), canola oil (24%), and fish oil (15%) (Test Group). Treatments were administered by gavage for four days pre-extraction and three days post-surgery. Animals were euthanized at 3, 7, 14, and 21 days post-extraction. Blood and tissue samples were analyzed for myeloperoxidase, osteoclast count, IL-1β, NFκB, iNOS, BMP-2 expression, glutathione (GSH), and thiobarbituric acid reactive substances (TBARS).</p><p><strong>Results: </strong>The Anti-inflammatory/Antioxidant mixture significantly reduced myeloperoxidase expression, osteoclast count, GSH, TBARS, and IL-1β levels on day 7. It also decreased NFκB, iNOS, and BMP-2 expression on days 3 and 7 compared to the Saline and Isolipidic groups.</p><p><strong>Conclusion: </strong>The Anti-inflammatory and Antioxidant mixture effectively reduced inflammation and oxidative stress during the inflammatory and proliferative phases of post-extraction healing, suggesting potential benefits in clinical applications for oral surgery recovery.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell therapy: a promising frontier in modern medicine with a comprehensive overview of their biology and potential therapeutic applications in chronic non-healing cutaneous injuries.","authors":"Qadeer Ahmad, Shumaila Mehdi, Malik Hassan Mehmood, Muhammad Talha Asif, Muhammad Mohsin Ali","doi":"10.1007/s10787-025-01924-6","DOIUrl":"https://doi.org/10.1007/s10787-025-01924-6","url":null,"abstract":"<p><p>Chronic wounds represent significant challenges to the healthcare system. Their incidence increases with increase in age, especially in individuals suffering from chronic disorders like diabetes. The process of wound healing consists of a series of coordinated biological events triggered by tissue damage, ultimately leading to the repair and restoration of damaged tissues. Various pharmacological and non-pharmacological interventions are employed for the management of chronic wounds. The clinical application of traditional therapeutic modalities for managing chronic wounds is limited due to the associated adverse effects, like antimicrobial resistance, pressure lesions, ear and nose barotrauma, and convulsions. Recent advancements in stem cell therapy hold promise for the management of chronic wounds. These are the undifferentiated cells of the human body with the capability of self-renewal. These cells migrate to the wounded site and transform into the required type of cell to repair the tissues. The use of autologous stem cells decreases the risk of immune rejection and infections. These cells do not carry the risk of transmitting contagious diseases from the donor. Various types of stem cells have been investigated in the management of chronic wounds using diverse modes. These cells can be administered topically on the wounded site or through various matrices, such as hydrogels, scaffolds, extracellular matrix derivatives, and dermal substitutes. These cells promote the healing process by acting directly or indirectly on various pathogenic targets in chronic wounds. This review aims to explore the potential of stem cells in chronic wound management, including diabetic foot ulcers, burn ulcers, pressure ulcers, inherited epidermolysis bullosa, and venous leg ulcers. This review also highlights the molecular and cellular pathways involved in wound healing discussed in this review. Moreover, various pre-clinical and clinical studies exploring the use of stem cells in chronic wounds are also reviewed. In sum, the current review weighs the limitations associated with traditional therapies and the merits of the potential application of stem cells in chronic wound management.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Ipomoea carnea Jacq. ameliorates formalin-induced paw inflammation in rats through modulation of oxidative and inflammatory pathways.","authors":"Shabab Nasir, Muhammad Usman, Humaira Gul, Malik Saadullah, Maryam Farrukh, Rida Siddique, Bushra Shaukat, Abdullah R Alanzi, Ana Sanches Silva, Muhammad Ajmal Shah","doi":"10.1007/s10787-025-01914-8","DOIUrl":"10.1007/s10787-025-01914-8","url":null,"abstract":"","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial.","authors":"Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari","doi":"10.1007/s10787-025-01919-3","DOIUrl":"10.1007/s10787-025-01919-3","url":null,"abstract":"<p><strong>Background: </strong>With few effective therapies, metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising worldwide health problem. Ellagic acid (EA), a polyphenol with antioxidant and anti-inflammatory properties, may address the multifactorial pathogenesis of MASLD. This trial evaluated the efficacy of EA supplementation combined with a hypocaloric diet in reducing hepatic fat and improving metabolic and liver function markers.</p><p><strong>Methods: </strong>In this double-blind, randomized, placebo-controlled study, 60 persons with MASLD participated. Included patients were randomly assigned to consume either 200 mg of EA once a day or a placebo, alongside a hypocaloric diet for 8 weeks. The primary outcome was the absolute mean change in HRI. Secondary outcomes included liver stiffness (LS), liver function tests, metabolic profile, high-sensitivity C-reactive protein (hs-CRP), and anthropometric indices.</p><p><strong>Results: </strong>EA supplementation significantly reduced HRI compared to the placebo group (mean difference [MD]: -0.23; P < 0.001). Improvements were also observed in LS (MD: - 0.47 kPa; P < 0.001), alanine transaminase (MD: - 27.89 U/L; P < 0.001), aspartate transaminase (MD: - 8.20 U/L; P < 0.001), fasting blood sugar (MD: - 6.78 mg/dL; P < 0.001), triglyceride (MD: - 42.65 mg/dL; P = 0.004), low-density lipoprotein cholesterol (MD: - 14.63 mg/dL; P = 0.026), high-density lipoprotein cholesterol (MD: + 3.38 mg/dL; P = 0.019), and hs-CRP (MD: - 0.81 mg/L; P < 0.001). Anthropometric indices improved significantly by week 8.</p><p><strong>Conclusions: </strong>EA supplementation, combined with a hypocaloric diet, effectively reduced hepatic fat and improved metabolic and liver function markers in patients with MASLD. EA represents a promising adjunct therapy for MASLD management, warranting further investigation.</p><p><strong>Trial registration: </strong>The trial was registered in the Iranian Registry of Clinical Trials (Trial identifier: IRCT20180103038199N16).</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"5583-5598"},"PeriodicalIF":5.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immuno-nutritional therapy in experimental autoimmune encephalomyelitis: a translational pathway to multiple sclerosis management.","authors":"Mansur Aliyu, Ali Akbar Saboor-Yaraghi, Muhammad Ibrahim Getso, Fatema Tuz Zohora","doi":"10.1007/s10787-025-01804-z","DOIUrl":"10.1007/s10787-025-01804-z","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic autoimmune disorder characterised by myelin degeneration in the central nervous system (CNS), leading to significant neurological impairment. Affecting approximately 2.8 million people globally and has a multifactorial aetiology involving genetic predispositions and environmental factors, particularly dietary influences. This review explores the emerging field of immuno-nutritional therapy as a novel approach for managing experimental autoimmune encephalomyelitis (EAE), a widely accepted animal model of MS. We highlight the therapeutic potential of key nutritional components, such as omega-3 fatty acids, polyphenols, and vitamins A and D, which have been shown to modulate immune responses and promote neuroprotection. These nutrients exert their effects by regulating cytokine profiles, enhancing regulatory T-cell (Treg) differentiation, and maintaining blood-brain barrier (BBB) integrity. Evidence suggests that dietary interventions can significantly modulate disease severity and progression in EAE, offering valuable insights into potential therapeutic strategies for MS patients. However, translating the findings from EAE models to human MS requires careful consideration of differences in immune responses and environmental factors. Future clinical trials designed to evaluate the long-term efficacy of dietary interventions across diverse MS populations are essential. By integrating immunomodulatory treatments with tailored nutritional strategies, there is a potential for innovative therapies that can alter disease trajectories and improve patient outcomes. A collaborative approach among nutrition scientists, immunologists, and neurologists could pave the way for effective immuno-nutritional therapies in MS management, enhancing the quality of life of those affected by this debilitating condition.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"4941-4964"},"PeriodicalIF":5.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Anti-rheumatic activity of pseudoephedrine (a substituted phenethylamine) in complete Freund's adjuvant-induced arthritic rats by down regulating IL-1β, IL-6 and TNF-α as well as upregulating IL-4 and IL-10.","authors":"Haseeb Ahsan, Hafiz Muhammad Irfan, Alamgeer, Muhammad Shahzad, Mulazim Hussain Asim, Muhammad Akram, Muhammad Shoaib Zafar","doi":"10.1007/s10787-025-01837-4","DOIUrl":"10.1007/s10787-025-01837-4","url":null,"abstract":"","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"5627"},"PeriodicalIF":5.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}